deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03664921

Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

A Phase II Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Investigating the Safety and Efficacy of Omnitram in Diabetic Neuropathy

Sponsor: DF/Net Research

Conditions Diabetic Neuropathies Neuropathic Pain Pain, Chronic
Interventions Omnitram Oral Tablet Placebo Oral Tablet
Updated 14 times since 2018 Last updated: Sep 21, 2021 Started: Nov 15, 2018 Primary completion: Aug 17, 2020 Completion: Aug 17, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Diabetic Neuropathies and Neuropathic Pain, this trial is completed. The trial is conducted by DF/Net Research and has accumulated 14 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jun 2019 · 6 months · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Apr 2020 · 6 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Oct 2020 · 4 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Apr 2022 · 6 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Oct 2021 — Apr 2022 [monthly]

    Completed PHASE2

▶ Show 9 earlier versions

  1. Jan 2021 — Oct 2021 [monthly]

    Completed PHASE2

  2. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Jun 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  5. Oct 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  6. Jun 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  7. Dec 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  8. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Oct 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • DF/Net Research
  • National Institute on Drug Abuse (NIDA)
  • Syntrix Biosystems, Inc.
Data source: Syntrix Biosystems, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations